1. Improving localization accuracy for non-invasive automated early left ventricular origin localization approach.
- Author
-
Zhou S, Wang R, Seagren A, Emmert N, Warren JW, MacInnis PJ, AbdelWahab A, and Sapp JL
- Abstract
Background: We previously developed a non-invasive approach to localize the site of early left ventricular activation origin in real time using 12-lead ECG, and to project the predicted site onto a generic LV endocardial surface using the smallest angle between two vectors algorithm (SA). Objectives: To improve the localization accuracy of the non-invasive approach by utilizing the K-nearest neighbors algorithm (KNN) to reduce projection errors. Methods: Two datasets were used. Dataset #1 had 1012 LV endocardial pacing sites with known coordinates on the generic LV surface and corresponding ECGs, while dataset #2 included 25 clinically-identified VT exit sites and corresponding ECGs. The non-invasive approach used "population" regression coefficients to predict the target coordinates of a pacing site or VT exit site from the initial 120-m QRS integrals of the pacing site/VT ECG. The predicted site coordinates were then projected onto the generic LV surface using either the KNN or SA projection algorithm. Results: The non-invasive approach using the KNN had a significantly lower mean localization error than the SA in both dataset #1 (9.4 vs. 12.5 mm, p < 0.05) and dataset #2 (7.2 vs. 9.5 mm, p < 0.05). The bootstrap method with 1,000 trials confirmed that using KNN had significantly higher predictive accuracy than using the SA in the bootstrap assessment with the left-out sample ( p < 0.05). Conclusion: The KNN significantly reduces the projection error and improves the localization accuracy of the non-invasive approach, which shows promise as a tool to identify the site of origin of ventricular arrhythmia in non-invasive clinical modalities., Competing Interests: JS: a co-holder of a patent for automated VT localization; no licensing, royalties or income currently or anticipated. Research funding from Biosense-Webster and Abbott (for clinical trial of catheter ablation of VT); modest speaker honoraria Medtronic, Biosense Webster, Abbott. AA: speaker honoraria Abbott, Medtronic. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Zhou, Wang, Seagren, Emmert, Warren, MacInnis, AbdelWahab and Sapp.)
- Published
- 2023
- Full Text
- View/download PDF